Outcomes of long‐term von Willebrand factor prophylaxis use in von Willebrand disease: A systematic literature review
- 26 March 2022
- journal article
- review article
- Published by Wiley in Haemophilia
- Vol. 28 (3) , 373-387
Abstract
Background: Von Willebrand Disease (VWD) is a common inherited bleeding disorder. Patients with VWD suffering from severe bleeding may benefit from the use of secondary long‐term prophylaxis.Aim: Systematically summarize the evidence on the clinical outcomes of secondary long‐term prophylaxis in patients with VWD and severe recurrent bleedings.Methods: We searched Medline and EMBASE through October 2019 for relevant randomized clinical trials (RCTs) and comparative observational studies (OS) assessing the effects of secondary long‐term prophylaxis in patients with VWD. We used Cochrane Risk of Bias (RoB) tool and the RoB for Non‐Randomized Studies of interventions (ROBINS‐I) tool to assess the quality of the included studies. We conducted random‐effects meta‐analyses and assessed the certainty of the evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach.Results: We included 12 studies. Evidence from one placebo controlled RCT suggested that VWD prophylaxis as compared to no prophylaxis reduced the rate of bleeding episodes (Rate ratio [RR], .24; 95% confidence interval [CI], .17–.35; low certainty evidence), and of epistaxis (RR, .38; 95%CI, .21–.67; moderate certainty evidence), and may increase serious adverse events RR 2.73 (95%CI .12–59.57; low certainty). Evidence from four before‐and‐after studies in which researchers reported comparative data suggested that VWD prophylaxis reduced the rate of bleeding (RR .34; 95%CI, .25–.46; very low certainty evidence).Conclusion: VWD prophylaxis treatment seems to reduce the risk of spontaneous bleeding, epistaxis, and hospitalizations. More RCTs should be conducted to increase the certainty in these benefits.Keywords
Funding Information
- American Society of Hematology
This publication has 20 references indexed in Scilit:
- Heavy menstrual bleeding and health-associated quality of life in women with von Willebrand's diseaseExperimental and Therapeutic Medicine, 2016
- Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapyBlood Coagulation & Fibrinolysis, 2015
- Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a cross‐sectional studyHaemophilia, 2015
- Wilate use in 47 children with von Willebrand disease: the North London paediatric haemophilia network experienceHaemophilia, 2014
- Efficacy and safety of Wilate in paediatric VWD patients under 6 years of age - results of a prospective multicentre clinical study including recovery informationHaemophilia, 2013
- Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand diseaseHaemophilia, 2012
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Clinical use of Haemate(R) P in inherited von Willebrand's disease: a cohort study on 100 Italian patientsHaematologica, 2007
- Long-term prophylaxis in von Willebrand diseaseBlood Coagulation & Fibrinolysis, 2005
- Efficacy and Safety of the Factor VIII/von Willebrand Factor Concentrate, Haemate-P/Humate-P: Ristocetin Cofactor Unit Dosing in Patients with von Willebrand DiseaseThrombosis and Haemostasis, 2002